Summary of Study ST004119
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002589. The data can be accessed directly via it's Project DOI: 10.21228/M80G2G This work is supported by NIH grant, U2C- DK119886. See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Study ID | ST004119 |
| Study Title | Bashaga Mongolian medicine anti-liver based on ' intestinal flora-tryptophan metabolism-liver axis ' Study on the mechanism of fiber action |
| Study Summary | Rhododendron molle (Blume) G. Don (abbreviated as RM), known as 'Bashaga' in traditional Mongolian medicine, was investigated. Mongolian medicine believes that liver fibrosis is caused by the interaction of 'liver-gut' between blood and heat meridians. 'Bashaga' is the main Mongolian medicine treatment for liver disease. There is still a lack of modern scientific research to clarify its effectiveness. The source and mechanism of action restrict the clinical development and rational utilization 'Bashaga'. Preliminary Studies have found that tryptophan metabolic pathway affects the occurrence and development of liver fibrosis. Previous research has shown that Bashaga acts by regulating the 'intestinal microbiota-tryptophan metabolism-liver axis'. This project intends to use a CCL4 induced liver fibrosis rat model, to evaluate the effect of 'Bashaga' by physiological and biochemical indexes such as pathology, liver injury and inflammatory factors. To study the efficacy of Bahsaga to treat liver fibrosis, the method of combining tryptophan-targeted metabolome with metagenome was used. We explored its regulation of intestinal flora structure, tryptophan metabolites and intestinal barrier by constructing the 'Intestinal flora-tryptophan metabolism-phenotypic function index' to reveal the anti-hepatic fibrosis effect of Bashaga. The purpose of this study is to clarify the original source and clinical rationality of Bashaga guided by efficacy. |
| Institute | Baotou Medical College |
| Last Name | Jiang |
| First Name | Xiaolei |
| Address | No. 31, Jianshe Road, Donghe District, Baotou, Inner Mongolia, 014040, China |
| jxl15147689596@163.com | |
| Phone | 15147689596 |
| Submit Date | 2025-07-26 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML, raw(Thermo) |
| Analysis Type Detail | LC-MS |
| Release Date | 2025-09-11 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
| Project ID: | PR002589 |
| Project DOI: | doi: 10.21228/M80G2G |
| Project Title: | Bashaga Mongolian medicine anti-liver based on 'intestinal flora-tryptophan metabolism-liver axis', Study on the mechanism of fiber action |
| Project Summary: | Rhododendron molle (Blume) G. Don (abbreviated as RM), known as 'Bashaga' in traditional Mongolian medicine, was investigated. Mongolian medicine believes that liver fibrosis is caused by the interaction of 'liver-gut' between blood and heat meridians. 'Bashaga' is the main Mongolian medicine treatment for liver disease. There is still a lack of modern scientific research to clarify its effectiveness. The source and mechanism of action restrict the clinical development and rational utilization of 'Bashaga'. Preliminary Studies have found that tryptophan metabolic pathway affects the occurrence and development of liver fibrosis. Previous research has shown that Bashaga acts by regulating the 'intestinal microbiota-tryptophan metabolism-liver axis'. This project intends to use a CCL4 induced liver fibrosis rat model, to evaluate the effect of 'Bashaga' by physiological and biochemical indexes such as pathology, liver injury and inflammatory factors. To study the efficacy of Bahsaga to treat liver fibrosis, the method of combining tryptophan-targeted metabolome with metagenome was used. We explored its regulation of intestinal flora structure, tryptophan metabolites and intestinal barrier by constructing the 'Intestinal flora-tryptophan metabolism-phenotypic function index' to reveal the anti-hepatic fibrosis effect of Bashaga. The purpose of this study is to clarify the original source and clinical rationality of Bashaga guided by efficacy. |
| Institute: | Baotou Medical College |
| Last Name: | Jiang |
| First Name: | Xiaolei |
| Address: | No. 31, Jianshe Road, Donghe District, Baotou, Inner Mongolia, 014040, China |
| Email: | jxl15147689596@163.com |
| Phone: | 15147689596 |
Subject:
| Subject ID: | SU004268 |
| Subject Type: | Mammal |
| Subject Species: | Rattus norvegicus |
| Taxonomy ID: | 10116 |
| Gender: | Male |
Factors:
Subject type: Mammal; Subject species: Rattus norvegicus (Factor headings shown in green)
| mb_sample_id | local_sample_id | Sample source | Sample source | Concentration | Treatment |
|---|---|---|---|---|---|
| SA476311 | QC_4 | feces | NA | NA | NA |
| SA476312 | QC_2 | feces | NA | NA | NA |
| SA476313 | QC_3 | feces | NA | NA | NA |
| SA476314 | QC_1 | feces | NA | NA | NA |
| SA476315 | QC_5 | feces | NA | NA | NA |
| SA476316 | QC_6 | feces | NA | NA | NA |
| SA476317 | QC_7 | feces | NA | NA | NA |
| SA476318 | QC_8 | feces | NA | NA | NA |
| SA476337 | MOD_5 | feces | normal saline | 0.90% | 40% CCl4 + corn oil（Two times each week） |
| SA476338 | MOD_6 | feces | normal saline | 0.90% | 40% CCl4 + corn oil（Two times each week） |
| SA476339 | MOD_4 | feces | normal saline | 0.90% | 40% CCl4 + corn oil（Two times each week） |
| SA476340 | MOD_3 | feces | normal saline | 0.90% | 40% CCl4 + corn oil（Two times each week） |
| SA476341 | MOD_2 | feces | normal saline | 0.90% | 40% CCl4 + corn oil（Two times each week） |
| SA476342 | MOD_1 | feces | normal saline | 0.90% | 40% CCl4 + corn oil（Two times each week） |
| SA476343 | CON_4 | feces | normal saline | 0.90% | NA |
| SA476344 | CON_3 | feces | normal saline | 0.90% | NA |
| SA476345 | CON_2 | feces | normal saline | 0.90% | NA |
| SA476346 | CON_5 | feces | normal saline | 0.90% | NA |
| SA476347 | CON_6 | feces | normal saline | 0.90% | NA |
| SA476348 | CON_1 | feces | normal saline | 0.90% | NA |
| SA476319 | RML_6 | feces | RM | 0.07875g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476320 | RML_5 | feces | RM | 0.07875g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476321 | RML_4 | feces | RM | 0.07875g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476322 | RML_3 | feces | RM | 0.07875g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476323 | RML_2 | feces | RM | 0.07875g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476324 | RML_1 | feces | RM | 0.07875g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476325 | RMH_3 | feces | RM | 0.315g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476326 | RMH_6 | feces | RM | 0.315g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476327 | RMH_5 | feces | RM | 0.315g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476328 | RMH_4 | feces | RM | 0.315g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476329 | RMH_2 | feces | RM | 0.315g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476330 | RMH_1 | feces | RM | 0.315g/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476331 | Sily_6 | feces | Sily | 100 mg/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476332 | Sily_5 | feces | Sily | 100 mg/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476333 | Sily_4 | feces | Sily | 100 mg/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476334 | Sily_3 | feces | Sily | 100 mg/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476335 | Sily_2 | feces | Sily | 100 mg/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| SA476336 | Sily_1 | feces | Sily | 100 mg/kg (body weight) | 40% CCl4 + corn oil（Two times each week） |
| Showing results 1 to 38 of 38 |
Collection:
| Collection ID: | CO004261 |
| Collection Summary: | Fresh feces were collected by pressing method before dissection of rats. |
| Sample Type: | Feces |
| Storage Conditions: | -80℃ |
Treatment:
| Treatment ID: | TR004277 |
| Treatment Summary: | Rats were treated with an extract of Rhododendron molle (Blume) G. Don (RM), silymarin (Sily) as positive control and normal saline as control. |
Sample Preparation:
| Sampleprep ID: | SP004274 |
| Sampleprep Summary: | After the fecal sample was taken out from the refrigerator at − 80 ° C, 100 mg of feces was taken, added with 1000 uL of 75 % methanol in a 1.5 mL centrifuge tube, homogenized, suspended for 30 s, and sonicated for 10 min. After centrifugation at 13,000 rpm, the supernatant was filtered through the membrane, and the first three drops were not used as samples for fecal analysis. |
Combined analysis:
| Analysis ID | AN006830 | AN006831 |
|---|---|---|
| Chromatography ID | CH005187 | CH005187 |
| MS ID | MS006529 | MS006530 |
| Analysis type | MS | MS |
| Chromatography type | Reversed phase | Reversed phase |
| Chromatography system | Waters Acquity I-Class | Waters Acquity I-Class |
| Column | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm, 1.8um) | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm, 1.8um) |
| MS Type | ESI | ESI |
| MS instrument type | Orbitrap | Orbitrap |
| MS instrument name | Thermo Q Exactive Orbitrap | Thermo Q Exactive Orbitrap |
| Ion Mode | POSITIVE | NEGATIVE |
| Units | normalized peak area | normalized peak area |
Chromatography:
| Chromatography ID: | CH005187 |
| Chromatography Comments: | ACQUITY UPLC HSS T3 ( 2.1× 100 mm，1. 8 μm) |
| Instrument Name: | Waters Acquity I-Class |
| Column Name: | Waters ACQUITY UPLC HSS T3 (100 x 2.1mm, 1.8um) |
| Column Temperature: | 30℃ |
| Flow Gradient: | 0-4min，1%-50% A；4-6min：50%-90% A，6-7min：90%-100%A，7-8：100%A |
| Flow Rate: | 5 microLiters/min |
| Solvent A: | 100% Acetonitrile; 0.1 % formic acid |
| Solvent B: | 100% Water; 0.1 % formic acid |
| Chromatography Type: | Reversed phase |
MS:
| MS ID: | MS006529 |
| Analysis ID: | AN006830 |
| Instrument Name: | Thermo Q Exactive Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | Progenesis QI software can be used to analyze the original data of metabolomics. The software can normalize the intensity of each ion relative to the total ion number, and generate a data matrix, which includes retention time, mass-to-charge ratio and normalized peak area, so as to obtain more insights and useful results. The data matrix was subjected to unsupervised principal component analysis ( PCA ) and supervised partial least squares-discriminant analysis ( PLS-DA ) using EZinfor software. |
| Ion Mode: | POSITIVE |
| MS ID: | MS006530 |
| Analysis ID: | AN006831 |
| Instrument Name: | Thermo Q Exactive Orbitrap |
| Instrument Type: | Orbitrap |
| MS Type: | ESI |
| MS Comments: | Progenesis QI software can be used to analyze the original data of metabolomics. The software can normalize the intensity of each ion relative to the total ion number, and generate a data matrix, which includes retention time, mass-to-charge ratio and normalized peak area, so as to obtain more insights and useful results. The data matrix was subjected to unsupervised principal component analysis ( PCA ) and supervised partial least squares-discriminant analysis ( PLS-DA ) using EZinfor software. |
| Ion Mode: | NEGATIVE |
